Protective barrier against shingles, symbolizing vaccine effectiveness

Shingles Vaccine: How Long Does Protection Last and What Are Your Options?

Samir D’Costa monogram
Samir D’Costa in Health & Wellness October 2026 • 4 min read.

"A new study sheds light on the long-term effectiveness of the herpes zoster subunit vaccine (HZ/su), offering valuable insights for older adults."


Shingles, a painful and debilitating condition caused by the reactivation of the varicella-zoster virus (VZV), poses a significant health risk to older adults. The virus, which remains dormant in the body after a chickenpox infection, can resurface later in life, leading to a painful rash and potential long-term complications. With an aging population, the need for effective preventive measures has become increasingly critical.

Vaccination has emerged as a powerful tool in preventing shingles and reducing its associated burden. Among the available options, the herpes zoster subunit vaccine (HZ/su), stands out for its efficacy and safety profile. This innovative vaccine combines varicella-zoster virus glycoprotein E (gE) with the AS01B Adjuvant System, stimulating a robust immune response to ward off shingles. But just how long does this protection last?

A recent study published in OFID 2014:1 (Suppl 1) has provided crucial insights into the long-term immunogenicity and safety of the HZ/su vaccine. The open-label, multicenter trial followed participants for up to six years after vaccination, assessing the persistence of vaccine-induced immune responses. The results offer a reassuring perspective on the durability of protection against shingles, helping inform vaccination decisions for older adults.

AI Search Multiple angles on this topic

Why Shingles Matters

Shingles is a painful condition caused by reactivation of the varicella-zoster virus. It can produce a blistering rash and may be followed by persistent nerve pain and other complications. The risk and impact are especially important for older adults, although individual outcomes vary.

Vaccination as Prevention

Vaccination is the standard preventive approach for shingles, but protection is not absolute and immune responses can vary between people. Decisions about vaccination may also depend on age, health status, and prior vaccination history. Patients should discuss the appropriate schedule and options with a healthcare professional.

From Chickenpox to Shingles Vaccines

Shingles results from reactivation of varicella-zoster virus, the same virus responsible for chickenpox, which remains in the body after the initial infection or, less commonly, after chickenpox vaccination. The disease can cause a painful blistering rash and persistent postherpetic neuralgia. The first shingles vaccine, Merck's live-attenuated Zostavax, was approved by the U.S. Food and Drug Administration in 2006 as a single dose for healthy Americans aged 60 and older without immune-system disorders. [Reference URL 1](https://en.wikipedia.org/wiki/Zoster_vaccine) [Reference URL 2](https://www.nvic.org/disease-vaccine/shingles/vaccine-history)

How Effective is the Shingles Vaccine (HZ/su) Over the Long Term?

Protective barrier against shingles, symbolizing vaccine effectiveness

The study, detailed in OFID 2014:1 (Suppl 1), tracked 129 subjects who had previously received two doses of HZ/su (50 µg gE + AS01B). Researchers evaluated the participants' immune responses at 48, 60, and 72 months after the initial dose, measuring both gE-specific cell-mediated immune (CMI) responses and anti-gE antibody concentrations. The findings revealed a promising trend: while immune responses decreased over time, they remained significantly higher than pre-vaccination levels.

Specifically, the median values for gE-specific CMI response at 72 months were 3.8 times higher than before vaccination. This indicates that the vaccine continues to provide a substantial level of immune protection for up to six years. These results align with the growing body of evidence supporting the long-term effectiveness of the HZ/su vaccine.

  • Sustained Immune Response: Even after six years, the vaccine continues to stimulate a higher immune response compared to pre-vaccination levels.
  • Cell-Mediated Immunity: The vaccine boosts the body's T cells, enhancing their ability to fight off the virus.
  • Antibody Production: The vaccine promotes the production of antibodies that target and neutralize the shingles virus.
AI Search Multiple angles on this topic

An Evolving Evidence Base

Research on shingles vaccination continues to examine how well vaccines prevent herpes zoster and related complications over time. Reviews may address effectiveness, safety, immune responses, and differences among patient groups. Because findings and recommendations can change, current clinical guidance remains important.

Limits and Safety Monitoring

The CDC recommends Shingrix, the recombinant zoster vaccine, for prevention of shingles and related complications, but vaccination can still be followed by side effects or other health concerns. The Vaccine Adverse Event Reporting System, jointly managed by the CDC and FDA, serves as an early-warning system for potential vaccine-safety problems. Earlier live-attenuated zoster vaccination produced an increase in varicella-zoster-virus-specific CD4+ T cells that peaked one to four weeks after immunization, illustrating that immune response and clinical protection are related but distinct considerations. [Reference URL 1](https://www.cdc.gov/shingles/hcp/vaccine-considerations/index.html) [Reference URL 2](https://www.cdc.gov/vaccine-safety/vaccines/shingles-herpes.html)

Comparing Vaccine Options

Shingles vaccine options differ in vaccine technology, eligibility considerations, dosing, and the evidence supporting their use. Comparisons should account for both expected protection and practical factors such as medical history and access. A healthcare professional can help determine which currently recommended option is appropriate.

The study also monitored the safety of the vaccine over the long term, recording any serious adverse events (SAEs) from months 48 to 72. Reassuringly, no vaccine-related SAEs were reported during this period, reinforcing the favorable safety profile of the HZ/su vaccine. These findings provide additional confidence in the vaccine's suitability for older adults.

Making Informed Decisions About Shingles Prevention

The findings from OFID 2014:1 (Suppl 1) emphasize the importance of vaccination as a preventive measure against shingles, particularly for older adults. The HZ/su vaccine has demonstrated sustained immunogenicity and a favorable safety profile, offering long-term protection against this debilitating condition. By consulting with healthcare professionals and staying informed about vaccination options, individuals can make proactive decisions to safeguard their health and well-being.

AI Search Multiple angles on this topic

What Recent Evidence Suggests

Recent publications continue to characterize recombinant zoster vaccine effectiveness and safety, particularly in aging populations. Research has also explored whether recombinant shingles vaccination may be associated with lower cardiovascular disease risk, although comparisons between vaccine recipients and non-recipients can be affected by study-design limitations. Post-marketing analyses are examining adverse-event profiles reported to the U.S. Vaccine Adverse Event Reporting System as vaccination shifted from live-attenuated Zostavax to recombinant Shingrix after 2017. [Reference URL 1](https://www.nature.com/articles/s41591-026-04606-0) [Reference URL 2](https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2026.1920596/full)

Access and Market Development

Market analyses describe the zoster vaccine sector as focused on preventing shingles caused by reactivation of varicella-zoster virus, particularly among aging populations. One reported trend is increased availability through pharmacies and retail clinics, which may make vaccination easier to obtain and support uptake. Industry forecasts for 2026 to 2035 identify products including Shingrix, Zostavax, and SkyZoster, alongside recombinant and live-attenuated vaccine categories. [Reference URL 1](https://www.marketresearchfuture.com/reports/shingles-vaccine-market-21912) [Reference URL 2](https://www.precedenceresearch.com/shingles-vaccine-market)

Unequal Immune Responses

Varicella-zoster virus becomes latent in dorsal root and cranial nerve ganglia after primary chickenpox infection and can later reactivate as shingles. A randomized trial reported that Brazilian patients with systemic sclerosis had a lower immune response to recombinant zoster vaccine than healthy controls. This finding highlights the challenge of applying protection estimates uniformly across people with different underlying immune conditions. [Reference URL 1](https://www.sciencedirect.com/science/article/abs/pii/S0264410X2300837X) [Reference URL 2](https://www.medpagetoday.com/rheumatology/generalrheumatology/121704)

Living With Shingles Risk

For individuals, shingles is more than a vaccination decision: reactivation can cause a painful rash and may lead to prolonged nerve pain. The possibility of complications can affect daily life and make prevention an important personal health consideration. Conversations with clinicians can help people weigh vaccination, medical history, and access in the context of their own circumstances.

What the long-term estimates say-and do not say

The efficacy estimates indicate that protection against shingles remained substantial across the reported follow-up, while being lower for the group vaccinated at age 70 or older than for the group vaccinated at age 50 or older. Because these are estimates for groups, they do not establish how long any one person's protection lasts.[1]

Immune-response measurements in the earlier trials had settled at levels above those before vaccination. That laboratory pattern describes immune responses; it is not itself a measure of whether an individual will avoid shingles.[1]

How long-term efficacy compares with earlier estimates

Earlier Phase 3 trial estimates covered a shorter follow-up period than the long-term follow-up estimates, so the figures describe protection across different time windows rather than a direct like-for-like comparison.[1]

The live attenuated vaccine's reported efficacy was measured over a shorter period, and its effectiveness waned substantially over time. That history provides context for why persistence of efficacy is a distinct question in long-term vaccine follow-up.[1]

What remains uncertain in long-term follow-up

  • Nearly half of participants from the original trials did not enroll in the long-term follow-up. The reported estimates therefore come from those who enrolled, and the available figures do not establish how closely they represent those who did not.[2]
  • Efficacy assessments used historical estimates of shingles incidence, and data for one follow-up year were lacking. How these features affect estimates across the full follow-up remains an open question from the stated limitations.[2]

Short answers on vaccine follow-up

Is Zostavax still available in the United States?

No. The live zoster vaccine Zostavax has not been available for use in the United States since November 18, 2020.[3]

How is the shingles vaccine given?

The vaccine is given as a two-dose series.[3]

Sources

  1. Final analysis of the ZOE-LTFU trial to 11 years post-vaccination: efficacy of the adjuvanted recombinant zoster vaccine against herpes zoster and related complications (pmc.ncbi.nlm.nih.gov)
  2. Long-term Protection Against Herpes Zoster by the Adjuvanted Recombinant Zoster Vaccine: Interim Efficacy, Immunogenicity, and Safety Results up to 10 Years After Initial Vaccination (pmc.ncbi.nlm.nih.gov)
  3. Shingles Vaccination | Shingles (Herpes Zoster) | CDC (www.cdc.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What makes the herpes zoster subunit vaccine (HZ/su) a strong choice for shingles prevention in older adults?

The herpes zoster subunit vaccine (HZ/su) is notable because of its efficacy and safety profile. It uses varicella-zoster virus glycoprotein E (gE) combined with the AS01B Adjuvant System to create a strong immune response, protecting against shingles. Studies, like the one in *OFID 2014:1 (Suppl 1)*, show it maintains a higher immune response compared to pre-vaccination levels for up to six years, suggesting lasting protection.

2

How long does the shingles vaccine (HZ/su) protect against shingles?

According to the study in *OFID 2014:1 (Suppl 1)*, the herpes zoster subunit vaccine (HZ/su) provides significant immune protection for up to six years after vaccination. While immune responses decrease over time, gE-specific cell-mediated immune (CMI) responses remain 3.8 times higher than pre-vaccination levels at 72 months, indicating sustained effectiveness.

3

What specific immune responses does the shingles vaccine (HZ/su) stimulate in the body?

The herpes zoster subunit vaccine (HZ/su) stimulates both cell-mediated immunity (CMI) and antibody production. It boosts the body's T cells through gE-specific CMI responses, enhancing their ability to fight off the varicella-zoster virus. It also promotes the production of antibodies that target and neutralize the shingles virus. The *OFID 2014:1 (Suppl 1)* study showed that even after six years, these immune responses remain significantly higher than before vaccination.

4

Besides effectiveness, what does the *OFID 2014:1 (Suppl 1)* study reveal about the safety of the shingles vaccine (HZ/su) for older adults?

The *OFID 2014:1 (Suppl 1)* study reinforces the favorable safety profile of the herpes zoster subunit vaccine (HZ/su). The study monitored participants for serious adverse events (SAEs) from months 48 to 72 and found no vaccine-related SAEs during this period. This data provides additional confidence in the vaccine's suitability for older adults, complementing its proven long-term effectiveness.

5

If someone had chickenpox earlier in life, how does the shingles vaccine (HZ/su) offer them protection later on?

After a chickenpox infection, the varicella-zoster virus (VZV) remains dormant in the body. It can reactivate later in life, causing shingles. The herpes zoster subunit vaccine (HZ/su) is designed to prevent this reactivation. It uses varicella-zoster virus glycoprotein E (gE) and the AS01B Adjuvant System to stimulate a robust immune response, even years after the initial chickenpox infection. This strengthened immunity helps prevent the virus from resurfacing as shingles, as demonstrated by the sustained immune responses reported in the *OFID 2014:1 (Suppl 1)* study.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.